Cowen and Company’s Taysha Gene Therapies TSHA Stock Holding History

Cowen and Company’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,550,000	Closed	-$4.45M	–	703
2024 Q1	$4.45M	Buy	+1,550,000	New	+$3.23M	0.17%	63

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Cowen and Company's TSHA Position: Q2 2024 in Review

Cowen and Company sold out of Taysha Gene Therapies (TSHA) in Q2 2024, closing a stake of 1,550,000 shares — an estimated $4.45M sold.

Cowen and Company first reported a position in TSHA in Q1 2024 and held it in 1 quarter. The position peaked at $4.45M in Q1 2024. 107 funds tracked by Wall St. Rank hold TSHA as of Q2 2024.

Cowen and Company reported no remaining Taysha Gene Therapies position as of Q2 2024 after selling out during the quarter.
Cowen and Company sold 1,550,000 Taysha Gene Therapies shares in Q2 2024, an estimated $4.45M.
Cowen and Company first reported a position in Taysha Gene Therapies in Q1 2024 and held it in 1 quarter.
Cowen and Company's Taysha Gene Therapies position peaked at $4.45M in Q1 2024.
107 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2024.

Based on Cowen and Company's 13F filing for Q2 2024, filed 7 Aug 2024.